UK Medicines Information
FDA approve teprotumumab-trbw for thyroid eye disease
Information type:
Media and commentaries
Source:
BioSpace
Specialities:
Endocrine system disorders | Eyes and vision
Summary
Approval of this human IgG1k monoclonal antibody that binds to insulin-like growth factor-1 was based on the results of two studies which found that 71% and 83% demonstrated a >2mm reduction in proptosis vs 20% and 10% for placebo for the two trials respectively.
UKMi comment
This treatment has not yet been filed for regulatory review in the EU.
Related links: